Afya Ltd (AFYA) Stock Analysis and Metrics

Sector: Consumer Defensive Industry: Education & Training Services CIK: 0001771007

Market Cap 46.97 Mn

P/E 6.02

P/S 0.07

Div. Yield 0.61

ROIC (Qtr) 0.00

Total Debt (Qtr) 378.57 Mn

Revenue Growth (1y) (Qtr) 20.42

Add ratio to table...

About

Afya Limited is a medical education and technology company in Brazil that supports physicians throughout their professional lifecycle, from medical school enrollment through residency preparation, graduate and specialization programs, continuing medical education, and clinical practice. The company combines traditional classroom instruction with digital platforms to deliver an integrated learning experience that spans the entire career of a medical professional. The company’s mission is to improve healthcare outcomes by providing continuous education...

Afya Limited is a medical education and technology company in Brazil that supports physicians throughout their professional lifecycle, from medical school enrollment through residency preparation, graduate and specialization programs, continuing medical education, and clinical practice. The company combines traditional classroom instruction with digital platforms to deliver an integrated learning experience that spans the entire career of a medical professional. The company’s mission is to improve healthcare outcomes by providing continuous education and technological support to medical professionals across Brazil. It leverages a hybrid model that blends in person teaching with digital resources to enhance learning accessibility and effectiveness.

Revenue is generated mainly from monthly tuition fees paid by undergraduate and continuing education students, which constitute the majority of the company’s income, and from subscription fees for its medical practice solutions such as clinical decision support tools and practice management software. Additional income comes from the sale of educational content, digital products, and services provided to third party institutions.

The company operates through the following segments.

• Undergraduate: This segment delivers undergraduate programs in medicine, health sciences, and other disciplines through a network of higher education institutions regulated by the Brazilian Ministry of Education, generating revenue from tuition fees charged to enrolled students.

• Continuing Education: This segment provides residency preparation courses, graduate programs, and continuing medical education via digital and in person platforms, serving physicians and medical students seeking ongoing professional development and earning revenue from subscription and course fees.

• Medical Practice Solutions: This segment offers clinical decision support platforms, practice management software, healthcare financial services, and digital ecosystem tools that help physicians manage their practices and improve patient care, with revenue derived from subscription fees paid by healthcare professionals.

Afya Limited holds the largest medical education footprint in Brazil based on the number of MEC approved medical school seats, with 3,755 seats as of the reporting date, surpassing competitors such as Player 1 with 2,060 seats, Player 2 with 1,867 seats, Player 3 with 1,069 seats, and Player 4 with 1,001 seats. The company’s integrated platform of education, technology and clinical solutions creates a differentiated position that is difficult to replicate due to regulatory barriers, a strong brand and a comprehensive ecosystem serving the full physician lifecycle.

The company serves a broad base of individual learners, including undergraduate and graduate medical students, residents and practicing physicians, as well as institutional clients such as third party medical schools, hospitals, and healthcare networks that adopt its educational content and digital tools. No specific customer names are disclosed in the filing, so the description focuses on the types of customers served.

Investment thesis

Bull case

Afya’s reported 100 percent occupancy across all medical programs signals a robust demand pipeline that is difficult to erode in the short term. The company’s 300,000 active users across Brazil indicate a healthy adoption rate among both students and physicians. A high occupancy rate translates directly into predictable tuition revenue and a stable operating cash flow that has grown 11 percent year over year. This operational resilience gives the firm an advantage over competitors that may still be dealing with underutilized capacity. Furthermore, the company’s ability to maintain full occupancy while adding new seats underscores an efficient scaling model that is likely to continue delivering incremental revenue.
Afya’s expansion to 3,753 approved seats, a near four percent increase in seat count, positions it well to capture more of Brazil’s growing medical education market. The recent approval of 100 seats in Afya Bragança illustrates the firm’s proactive engagement with regulatory bodies and its capability to secure new locations quickly. This seat expansion not only increases headcount but also enhances the company’s bargaining power with suppliers and technology partners. As the average ticket per student grows by over three percent, the revenue per seat is expected to lift proportionally. The incremental seat count, combined with higher ticket pricing, sets the stage for a compound growth trajectory that can sustain profitability.
The company’s revenue diversification into B2B and B2P channels has expanded to include a 65 percent increase in B2B revenue and an 11 percent lift in B2P revenue, providing multiple streams of income beyond tuition. The 65 percent B2B growth, driven by corporate partnerships and continuing education contracts, highlights the firm’s ability to generate high‑margin, long‑term contracts. The B2P segment, comprising 94 percent of health‑related courses, reflects strong physician engagement and cross‑sell opportunities. This mix reduces concentration risk associated with tuition alone and supports higher profitability margins. The diversified revenue base positions Afya to navigate fluctuations in any single market segment more effectively.
Afya’s adjusted EBITDA margin expanded to 46.4 percent, a 200 basis point increase over the same period last year, signaling improved cost discipline. The margin growth is attributed to higher gross margins in both undergraduate and continuing education, as well as efficient restructuring of the medical practice solutions segment. Stronger operating cash conversion, at 101.5 percent, indicates that the company is converting revenue into cash efficiently, further supporting margin expansion. The consistent improvement in profitability metrics reflects effective execution of the company’s cost control initiatives and scaling benefits from increased seat utilization. These margin gains provide a solid foundation for future expansion and shareholder returns.
Afya generated a record cash flow from operating activities of BRL 1.292 billion, an 11 percent rise year over year, while maintaining a low cost of debt at 106 percent of CDI. The company’s net debt fell to BRL 1.342 billion, a reduction of BRL 473 million, enhancing its financial flexibility for future investment or share repurchases. Management’s discussion of an active capital allocation strategy that balances buyback programs with potential dividends reflects a commitment to delivering value to shareholders. The liquidity position, combined with the ability to issue commercial notes and repay higher‑cost debt, provides a cushion against short‑term cash needs. These cash flow strengths empower Afya to pursue growth opportunities such as new campus openings or strategic acquisitions.

Afya’s reported 100 percent occupancy across all medical programs signals a robust demand pipeline that is difficult to erode in the short term. The company’s 300,000 active users across Brazil indicate a healthy adoption rate among both students and physicians. A high occupancy rate translates directly into predictable tuition revenue and a stable operating cash flow that has grown 11 percent year over year. This operational resilience gives the firm an advantage over competitors that may still be dealing with underutilized capacity. Furthermore, the company’s ability to maintain full occupancy while adding new seats underscores an efficient scaling model that is likely to continue delivering incremental revenue.
Afya’s expansion to 3,753 approved seats, a near four percent increase in seat count, positions it well to capture more of Brazil’s growing medical education market. The recent approval of 100 seats in Afya Bragança illustrates the firm’s proactive engagement with regulatory bodies and its capability to secure new locations quickly. This seat expansion not only increases headcount but also enhances the company’s bargaining power with suppliers and technology partners. As the average ticket per student grows by over three percent, the revenue per seat is expected to lift proportionally. The incremental seat count, combined with higher ticket pricing, sets the stage for a compound growth trajectory that can sustain profitability.
The company’s revenue diversification into B2B and B2P channels has expanded to include a 65 percent increase in B2B revenue and an 11 percent lift in B2P revenue, providing multiple streams of income beyond tuition. The 65 percent B2B growth, driven by corporate partnerships and continuing education contracts, highlights the firm’s ability to generate high‑margin, long‑term contracts. The B2P segment, comprising 94 percent of health‑related courses, reflects strong physician engagement and cross‑sell opportunities. This mix reduces concentration risk associated with tuition alone and supports higher profitability margins. The diversified revenue base positions Afya to navigate fluctuations in any single market segment more effectively.
Afya’s adjusted EBITDA margin expanded to 46.4 percent, a 200 basis point increase over the same period last year, signaling improved cost discipline. The margin growth is attributed to higher gross margins in both undergraduate and continuing education, as well as efficient restructuring of the medical practice solutions segment. Stronger operating cash conversion, at 101.5 percent, indicates that the company is converting revenue into cash efficiently, further supporting margin expansion. The consistent improvement in profitability metrics reflects effective execution of the company’s cost control initiatives and scaling benefits from increased seat utilization. These margin gains provide a solid foundation for future expansion and shareholder returns.
Afya generated a record cash flow from operating activities of BRL 1.292 billion, an 11 percent rise year over year, while maintaining a low cost of debt at 106 percent of CDI. The company’s net debt fell to BRL 1.342 billion, a reduction of BRL 473 million, enhancing its financial flexibility for future investment or share repurchases. Management’s discussion of an active capital allocation strategy that balances buyback programs with potential dividends reflects a commitment to delivering value to shareholders. The liquidity position, combined with the ability to issue commercial notes and repay higher‑cost debt, provides a cushion against short‑term cash needs. These cash flow strengths empower Afya to pursue growth opportunities such as new campus openings or strategic acquisitions.

Bear case

Afya’s effective tax rate increased from 5.1 percent to 9.7 percent during the nine‑month period, largely due to provisions for Brazil’s Pillar Two minimum tax. Management signals that from 2026 onward, the effective rate could converge to the minimum 15 percent, imposing a higher tax burden on future earnings. This tax escalation could compress net income and reduce the ability to fund growth or return capital to shareholders. The company’s financial projections may have under‑assessed the impact of this new tax regime, creating potential upside risk for investors. Consequently, the tax shift represents a structural headwind that could diminish profitability margins over time.
Afya’s expansion is contingent upon continued seat approvals from Brazil’s education authorities, a process that can be protracted and subject to policy changes. Delays or rejections in obtaining new seats could stall campus openings and stall revenue growth. The company’s reliance on frequent approvals introduces a cyclical risk that could disrupt its expansion timeline. Management’s emphasis on seat approvals during the call indicates awareness of this vulnerability. Investors should consider that regulatory bottlenecks could materially impact future seat counts and associated revenue.
Afya maintains a stable FIES penetration of around seventeen to eighteen percent, which, while providing tuition stability, exposes the company to policy shifts in federal student financing. A reduction in FIES funding or tightening of eligibility criteria could increase tuition risk for a significant portion of the student body. The firm’s reliance on public financing makes it sensitive to changes in government budgets and educational policy. Such shifts could erode enrollment numbers or compel the company to adjust tuition, potentially impacting revenue growth. Therefore, FIES dependency represents a notable financial risk.
New private medical schools and digital education platforms are entering the market, intensifying competition for both seats and continuing education contracts. As price sensitivity rises, Afya may face pressure to lower tuition or offer additional value propositions, squeezing margins. The company’s dominant position could erode if competitors replicate its integrated ecosystem model or leverage technology to attract students and physicians. Competition also threatens the company's B2B contracts, which may be negotiated at lower prices or with stricter terms. These dynamics could reduce Afya’s market share and profitability over time.
Although current demand for medical education remains strong, broader societal trends suggest a possible shift in career preferences away from medicine, driven by rising debt levels and alternative professional opportunities. A sustained decline in interest could reduce the pipeline of new students, affecting seat utilization and enrollment growth. The firm’s revenue forecasts depend on a continuous intake of students; a decline could slow tuition revenue growth. While the company has not yet seen a clear trend, the potential for reduced demand remains an untested risk that could materialize under macroeconomic pressure.

Afya’s effective tax rate increased from 5.1 percent to 9.7 percent during the nine‑month period, largely due to provisions for Brazil’s Pillar Two minimum tax. Management signals that from 2026 onward, the effective rate could converge to the minimum 15 percent, imposing a higher tax burden on future earnings. This tax escalation could compress net income and reduce the ability to fund growth or return capital to shareholders. The company’s financial projections may have under‑assessed the impact of this new tax regime, creating potential upside risk for investors. Consequently, the tax shift represents a structural headwind that could diminish profitability margins over time.
Afya’s expansion is contingent upon continued seat approvals from Brazil’s education authorities, a process that can be protracted and subject to policy changes. Delays or rejections in obtaining new seats could stall campus openings and stall revenue growth. The company’s reliance on frequent approvals introduces a cyclical risk that could disrupt its expansion timeline. Management’s emphasis on seat approvals during the call indicates awareness of this vulnerability. Investors should consider that regulatory bottlenecks could materially impact future seat counts and associated revenue.
Afya maintains a stable FIES penetration of around seventeen to eighteen percent, which, while providing tuition stability, exposes the company to policy shifts in federal student financing. A reduction in FIES funding or tightening of eligibility criteria could increase tuition risk for a significant portion of the student body. The firm’s reliance on public financing makes it sensitive to changes in government budgets and educational policy. Such shifts could erode enrollment numbers or compel the company to adjust tuition, potentially impacting revenue growth. Therefore, FIES dependency represents a notable financial risk.
New private medical schools and digital education platforms are entering the market, intensifying competition for both seats and continuing education contracts. As price sensitivity rises, Afya may face pressure to lower tuition or offer additional value propositions, squeezing margins. The company’s dominant position could erode if competitors replicate its integrated ecosystem model or leverage technology to attract students and physicians. Competition also threatens the company's B2B contracts, which may be negotiated at lower prices or with stricter terms. These dynamics could reduce Afya’s market share and profitability over time.
Although current demand for medical education remains strong, broader societal trends suggest a possible shift in career preferences away from medicine, driven by rising debt levels and alternative professional opportunities. A sustained decline in interest could reduce the pipeline of new students, affecting seat utilization and enrollment growth. The firm’s revenue forecasts depend on a continuous intake of students; a decline could slow tuition revenue growth. While the company has not yet seen a clear trend, the potential for reduced demand remains an untested risk that could materialize under macroeconomic pressure.

Segments [axis] Breakdown of Revenue (2025)

Peer comparison

Companies in the Education & Training Services

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	COE	51Talk Online Education Group	7.64 Bn	-526.17	79.87	3.33 Mn
2	GHC	Graham Holdings Co	4.92 Bn	16.64	0.99	821.98 Mn
3	LAUR	Laureate Education, Inc.	4.86 Bn	17.98	2.80	215.84 Mn
4	CVSA	Covista Inc.	4.36 Bn	19.34	2.28	499.47 Mn
5	LRN	Stride, Inc.	4.16 Bn	13.51	1.64	417.58 Mn
6	LOPE	Grand Canyon Education, Inc.	3.97 Bn	18.50	3.53	-
7	UTI	Universal Technical Institute Inc	2.35 Bn	54.29	2.70	130.73 Mn
8	PRDO	PERDOCEO EDUCATION Corp	2.13 Bn	12.78	2.50	-

Research Tools

Developers

Afya Ltd (NASDAQ: AFYA)

About

Investment thesis

Bull case

Bear case

Segments [axis] Breakdown of Revenue (2025)

Segments [axis] Breakdown of Revenue (2025)

Peer comparison

Research Tools

Developers

Afya Ltd (NASDAQ: AFYA)

About

Investment thesis

Bull case

Bear case

Segments [axis] Breakdown of Revenue (2025)

Segments [axis] Breakdown of Revenue (2025)

Peer comparison

Create an account

Sign In

Reset Password